Colombian decree will allow 'non-comparable' biologics, say R&D firms
This article was originally published in Scrip
Executive Summary
The publication of a Colombian decree on the evaluation of biotechnological medicines has caused something of a stir, not least because it offers three separate approval pathways, one of which R&D-based companies say will allow the approval of "non-comparable" versions of originator biologic medicines.